Literature DB >> 22953021

Changes in the safety paradigm with percutaneous coronary interventions in the modern era: Lessons learned from the ASCERT registry.

Alfredo E Rodríguez1, Carlos Fernández-Pereira, Alfredo M Rodríguez-Granillo.   

Abstract

In the past, comparative effectiveness trials evaluating percutaneous coronary interventions (PCI), using either balloon angioplasty or bare metal stent (BMS) implantation, versus coronary artery bypass surgery (CABG) found similar survival rates at long-term follow-up with both revascularization strategies. Two major meta-analyses of these trials reported 5- and 6-year comparative effectiveness between PCI and CABG: one included only four trials that compared PCI with BMS implantation versus CABG whereas the largest one also included trials using balloon angioplasty. In these studies, the authors observed no survival differences between groups although a significant survival advantage was seen in diabetics treated with CABG and this benefit was also perceived in elderly patients. In both reports, number of involved vessels, presence of left anterior descending artery stenosis or poor left ventricular ejection fraction were no predictors of poor survival with PCI. Therefore, extent of the coronary artery disease (CAD) was not associated with poor outcome after PCI in the pre-drug eluting stent (DES) era. Recently, the ASCERT (Database Collaboration on the Comparative Effectiveness of Revascularization Strategies) registry found higher mortality rate with PCI in patients ≥ 65 years old in comparison with CABG, and advantages of surgery were seen in all subgroups including those at low risk. In this registry, PCI was accomplished by implantation of the first type of DES designs in 78% of cases. The intriguing observation of high mortality rate with PCI, including for non-diabetics and patients with two-vessel CAD, meaning a lack of clinical benefit with DES implantation, had not been seen previously. The study was not randomized, although its results are largely strengthened by its sample size. In this manuscript, the authors describe other registries and randomized trials reporting similar results supporting the findings of the aforementioned study and explore the reasons for these results, while also searching for potential solutions.

Entities:  

Keywords:  Coronary artery bypass surgery; Coronary artery disease; Drug eluting stents; Elderly patients; Percutaneous coronary interventions

Year:  2012        PMID: 22953021      PMCID: PMC3432881          DOI: 10.4330/wjc.v4.i8.242

Source DB:  PubMed          Journal:  World J Cardiol


  34 in total

1.  Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II).

Authors:  Alfredo E Rodriguez; Julio Baldi; Carlos Fernández Pereira; Jose Navia; Máximo Rodriguez Alemparte; Alejandro Delacasa; Federico Vigo; Daniel Vogel; William O'Neill; Igor F Palacios
Journal:  J Am Coll Cardiol       Date:  2005-08-16       Impact factor: 24.094

2.  Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease.

Authors: 
Journal:  N Engl J Med       Date:  1996-07-25       Impact factor: 91.245

Review 3.  Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern.

Authors:  Edoardo Camenzind; P Gabriel Steg; William Wijns
Journal:  Circulation       Date:  2007-03-07       Impact factor: 29.690

4.  Comparative effectiveness of revascularization strategies.

Authors:  William S Weintraub; Maria V Grau-Sepulveda; Jocelyn M Weiss; Sean M O'Brien; Eric D Peterson; Paul Kolm; Zugui Zhang; Lloyd W Klein; Richard E Shaw; Charles McKay; Laura L Ritzenthaler; Jeffrey J Popma; John C Messenger; David M Shahian; Frederick L Grover; John E Mayer; Cynthia M Shewan; Kirk N Garratt; Issam D Moussa; George D Dangas; Fred H Edwards
Journal:  N Engl J Med       Date:  2012-03-27       Impact factor: 91.245

5.  Outcomes and complications associated with off-label and untested use of drug-eluting stents.

Authors:  Nirat Beohar; Charles J Davidson; Kevin E Kip; Lynne Goodreau; Helen Aslanidou Vlachos; Sheridan N Meyers; Keith H Benzuly; James D Flaherty; Mark J Ricciardi; Charles L Bennett; David O Williams
Journal:  JAMA       Date:  2007-05-09       Impact factor: 56.272

6.  Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents.

Authors:  Htut K Win; Angel E Caldera; Kelly Maresh; John Lopez; Charanjit S Rihal; Manish A Parikh; Juan F Granada; Sachin Marulkar; Deborah Nassif; David J Cohen; Neal S Kleiman
Journal:  JAMA       Date:  2007-05-09       Impact factor: 56.272

7.  Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS).

Authors:  Jean Booth; Tim Clayton; John Pepper; Fiona Nugara; Marcus Flather; Ulrich Sigwart; Rodney H Stables
Journal:  Circulation       Date:  2008-07-07       Impact factor: 29.690

8.  Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials.

Authors:  Joost Daemen; Eric Boersma; Marcus Flather; Jean Booth; Rod Stables; Alfredo Rodriguez; Gaston Rodriguez-Granillo; Whady A Hueb; Pedro A Lemos; Patrick W Serruys
Journal:  Circulation       Date:  2008-08-25       Impact factor: 29.690

9.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

Authors:  Jeffrey W Moses; Martin B Leon; Jeffrey J Popma; Peter J Fitzgerald; David R Holmes; Charles O'Shaughnessy; Ronald P Caputo; Dean J Kereiakes; David O Williams; Paul S Teirstein; Judith L Jaeger; Richard E Kuntz
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

10.  Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.

Authors:  P Michael Ho; Eric D Peterson; Li Wang; David J Magid; Stephan D Fihn; Greg C Larsen; Robert A Jesse; John S Rumsfeld
Journal:  JAMA       Date:  2008-02-06       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.